Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ranibizumab

Nature Reviews Drug Discovery volume 5, pages 815–816 (2006)Cite this article

Ranibizumab (Lucentis; Genentech), a humanized monoclonal antibody fragment that binds to vascular endothelial growth factor, was approved by the US FDA in June 2006 for the treatment of patients with neovascular age-related macular degeneration.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Neovascular AMD.

References

  1. Congdon, N. et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122, 477–485 (2004).

    Article  Google Scholar 

  2. Fine, S. L. et al. Age-related macular degeneration. N. Engl. J. Med. 342, 483–492 (2000).

    Article  CAS  Google Scholar 

  3. Fine, S. L., Martin, D. F. & Kirkpatrick, P. Pegaptanib sodium. Nature Rev. Drug Discov. 4, 187–188 (2005).

    Article  CAS  Google Scholar 

  4. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).

    Article  CAS  Google Scholar 

  5. Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480–1487 (1994).

    Article  CAS  Google Scholar 

  6. Adamis, A. P. et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66–71 (1996).

    Article  CAS  Google Scholar 

  7. Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865–881 (1999).

    Article  CAS  Google Scholar 

  8. Gaudreault, J. et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726–733 (2005).

    Article  Google Scholar 

  9. FDA labelling information [online], (2006).

  10. Gragoudas, E. S. et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).

    Article  CAS  Google Scholar 

  11. Michels, S. et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112, 1035–1047 (2005).

    Article  Google Scholar 

  12. Spaide, R. F. et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26, 383–390 (2006).

    PubMed  Google Scholar 

  13. IMS Health, IMS MIDAS Quantum, MAT (June 2006).

Download references

Author information

Authors and Affiliations

  1. the LV Prasad Eye Institute, Banjara Hills, Hyderabad, India

    Raja Narayanan

  2. the Department of Ophthalmology, University of California, Irvine, 92697, California, USA

    Baruch D. Kuppermann

  3. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole Jones

  4. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Raja Narayanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baruch D. Kuppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carole Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Narayanan, R., Kuppermann, B., Jones, C. et al. Ranibizumab. Nat Rev Drug Discov 5, 815–816 (2006). https://doi.org/10.1038/nrd2157

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2157

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing